The SMGT-GLP-1 nano microneedle patch represents a cutting-edge advancement in drug delivery technology
The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in adults with overweight or obesity and established heart disease (Lincoff et al., SELECT trial, New England Journal of Medicine , 2023)
For the first time, weight loss at this scale comes in a form that fits in a pocket
GLP-1 Weight loss: How GLP-1 medication can help you achieve sustainable weight loss GLP-1 Weight loss: How GLP-1 medication can help you achieve sustainable weight loss Want to know more about GLP-1 weight loss after watching Oprah Winfrey's "Shame, Blame and the Weight Loss Revolution" special
Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways
Alogliptin after acute coronary syndrome in patients with type 2 diabetes